Tags

Type your tag names separated by a space and hit enter

Drug use in pregnant women-a pilot study of the coherence between reported use of drugs and presence of drugs in plasma.
Eur J Clin Pharmacol 2018; 74(4):535-539EJ

Abstract

PURPOSE

In Sweden, information on drug use during pregnancy is obtained through an interview and recorded in a standardized medical record at every visit to the antenatal care clinic throughout the pregnancy. Antenatal, delivery, and neonatal records constitute the basis for the Swedish Medical Birth Register (MBR). The purpose of this exploratory study was to investigate the reliability of reported drug use by simultaneous screening for drug substances in the blood stream of the pregnant woman and thereby validate self-reported data in the MBR.

METHODS

Plasma samples from 200 women were obtained at gestational weeks 10-12 and 25 and screened for drugs by using ultra-high performance liquid chromatography with time of flight mass spectrometry (UHPLC-TOF-MS). The results from the analysis were then compared to medical records.

RESULTS

At the first sampling occasion, the drugs found by screening had been reported by 86% of the women and on the second sampling, 85.5%. Missed reported information was clearly associated with drugs for occasional use. The most common drugs in plasma taken in early and mid-pregnancy were meclizine and paracetamol. Two types of continuously used drugs, selective serotonin reuptake inhibitors and propranolol, were used. All women using them reported it and the drug screening revealed a 100% coherence.

CONCLUSIONS

This study shows good coherence between reported drug intake and the drugs found in plasma samples, which in turn positively validates the MBR.

Authors+Show Affiliations

Department of Obstetrics and Gynecology and Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden.Department of Obstetrics and Gynecology and Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden.Department of Forensic Genetics and Forensic Toxicology, National Board of Forensic Medicine, Linköping, Sweden. Department of Physics, Chemistry and Biology, Linköping University, Linköping, Sweden.Department of Obstetrics and Gynecology and Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden.Department of Clinical Pharmacology and Department of Medical and Health Sciences, Linköping University, Linköping, Sweden. margareta.reis@liu.se.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

29264642

Citation

Wolgast, Emelie, et al. "Drug Use in Pregnant Women-a Pilot Study of the Coherence Between Reported Use of Drugs and Presence of Drugs in Plasma." European Journal of Clinical Pharmacology, vol. 74, no. 4, 2018, pp. 535-539.
Wolgast E, Josefsson A, Josefsson M, et al. Drug use in pregnant women-a pilot study of the coherence between reported use of drugs and presence of drugs in plasma. Eur J Clin Pharmacol. 2018;74(4):535-539.
Wolgast, E., Josefsson, A., Josefsson, M., Lilliecreutz, C., & Reis, M. (2018). Drug use in pregnant women-a pilot study of the coherence between reported use of drugs and presence of drugs in plasma. European Journal of Clinical Pharmacology, 74(4), pp. 535-539. doi:10.1007/s00228-017-2402-4.
Wolgast E, et al. Drug Use in Pregnant Women-a Pilot Study of the Coherence Between Reported Use of Drugs and Presence of Drugs in Plasma. Eur J Clin Pharmacol. 2018;74(4):535-539. PubMed PMID: 29264642.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Drug use in pregnant women-a pilot study of the coherence between reported use of drugs and presence of drugs in plasma. AU - Wolgast,Emelie, AU - Josefsson,Ann, AU - Josefsson,Martin, AU - Lilliecreutz,Caroline, AU - Reis,Margareta, Y1 - 2017/12/20/ PY - 2017/05/09/received PY - 2017/12/08/accepted PY - 2017/12/22/pubmed PY - 2018/9/5/medline PY - 2017/12/22/entrez KW - Drug screening KW - Drug utilization KW - Interview KW - Pregnancy KW - Time of flight mass spectrometry SP - 535 EP - 539 JF - European journal of clinical pharmacology JO - Eur. J. Clin. Pharmacol. VL - 74 IS - 4 N2 - PURPOSE: In Sweden, information on drug use during pregnancy is obtained through an interview and recorded in a standardized medical record at every visit to the antenatal care clinic throughout the pregnancy. Antenatal, delivery, and neonatal records constitute the basis for the Swedish Medical Birth Register (MBR). The purpose of this exploratory study was to investigate the reliability of reported drug use by simultaneous screening for drug substances in the blood stream of the pregnant woman and thereby validate self-reported data in the MBR. METHODS: Plasma samples from 200 women were obtained at gestational weeks 10-12 and 25 and screened for drugs by using ultra-high performance liquid chromatography with time of flight mass spectrometry (UHPLC-TOF-MS). The results from the analysis were then compared to medical records. RESULTS: At the first sampling occasion, the drugs found by screening had been reported by 86% of the women and on the second sampling, 85.5%. Missed reported information was clearly associated with drugs for occasional use. The most common drugs in plasma taken in early and mid-pregnancy were meclizine and paracetamol. Two types of continuously used drugs, selective serotonin reuptake inhibitors and propranolol, were used. All women using them reported it and the drug screening revealed a 100% coherence. CONCLUSIONS: This study shows good coherence between reported drug intake and the drugs found in plasma samples, which in turn positively validates the MBR. SN - 1432-1041 UR - https://www.unboundmedicine.com/medline/citation/29264642/Drug_use_in_pregnant_women-a_pilot_study_of_the_coherence_between_reported_use_of_drugs_and_presence_of_drugs_in_plasma L2 - https://dx.doi.org/10.1007/s00228-017-2402-4 DB - PRIME DP - Unbound Medicine ER -